Here are the reasons for top movers today
AInvestMonday, Jan 8, 2024 5:40 pm ET
1min read
AMAM --
DADA --
DTC --
HARP --

ARDX stock gained on Jan 08, 2024 as the company provided positive updates on the commercial performance and outlook of its drug IBSRELA. In a presentation and webcast, Ardelyx estimated IBSRELA annual net sales to reach over $1 billion and reiterated FY2024 guidance of $140-150 million.

$HARP(HARP)$AMAM(AMAM)$DADA(DADA)$DTC(DTC)

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.